Far more detail about this news with some concrete numbers can be found in the above link.
Useful information concerning turn around time, machine speed, and most importantly I think a demonstration of the speed, with which they derived structural variations I guess because of their read lengths. It appears this comes pretty much for free with PACB, no long compute times for assembly. Nice demonstration of capability even though it is a very small organism it sets something of a benchmark in turnaround.
I am a group leader in a large diagnostic company and have a lot of Nextgen sequencing experience. The TAT for an organism like this would be similar with the Illumina GA as with the PacBio machine. The great benefit of the PacBio machine is long sequencing reads so homologous regions of the genome are easier to map. Furthermore, the real-time single molecule application can become extremely useful especially when doing cancer diagnostics and you're dealing with a high mosaicism issue. I haven't pulled the trigger on the stock yet but am patiently waiting to see how some of the first reviews of the technology come out.
Can any of you more educated posters help me with this question. Would any of the current sequencing technologies (LIFE, ILMN) have been able to determine the sequence of this bug as quickly as PACB? In other words is this story just hype or does it point to the true capabilities of this sytem and superiority over current technologies?
This story, it appears, speaks to one of the strengths of the platform without being useful for other comparisons. Overtime I am sure more information will surface about exact metrics and cost per base in the context of other stories.
In the meantime the stock seems to be giving good gains.